Table 3.
Current RC48 clinical trials for multiple autoimmune disease.
| Register number | Disease | State of the cancer | HER2 state | Therapeutic schedule | Clinical phase | Region |
|---|---|---|---|---|---|---|
| CTR20202569 | GC | A | IHC 2+/3+ | monotherapy | III | China |
| CTR20180844 | GC | A | IHC 2+/3+ | monotherapy | II | USA |
| CTR20200646 | BC | A | IHC 1+ | monotherapy | III | China |
| CTR20180492 | BC | A with liver metastasis | + | monotherapy | III | China |
| CRT20161035 | BC | A | IHC 1+ or + | monotherapy | Ib | China |
| CTR20182469 | UC | A | IHC 2+/3+ | monotherapy | II | China |
| ChiCTR2200055403 | UC | A | not detected | combination therapy | II | China |
| CTR20192667 | UC | A | + | monotherapy | II | USA |
| CTR20190939 | NSCLC | A | (IHC2+/3+) or mutation | monotherapy | Ib | China |
| CTR20192057 | BTC | A With failure of first-line chemotherapy | (IHC 2+/3+) | monotherapy | II | China |
| CTR20212908 | MM | A | IHC 2+/3+ | monotherapy | IIa | China |
| CTR20211602 | GMT | A | + OR IHC 1+ | monotherapy | II | China |
BC: breast cancer; GC: gastric cancer; UC: urothelial cancer; BTC: biliary tract cancer; NSCLC: non-small cell lung cancer; MM: malignant melanoma; GMT: gynecologic malignant tumor.
A: the state of the cancer is locally advanced or metastatic; IHC 2+/3+: HER2 overexpression; IHC 1+: HER2 low expression; +: HER2 positive; -: HER2 negative.